Literature DB >> 30600322

A practical guide to biomarkers for the evaluation of colorectal cancer.

Wei Chen1, Wendy L Frankel2.   

Abstract

Evaluation of microsatellite instability (MSI) of every colorectal cancer (CRC) is important for prognostic and therapeutic purposes, while molecular testing helps identify actionable targeted therapy for patients with metastatic disease. This review will discuss the biomarkers commonly encountered in the clinical evaluation of CRC, and practical issues regarding MSI screening, reporting, interpretation, molecular test indication, and specimen requirements.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30600322     DOI： 10.1038/s41379-018-0136-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


  9 in total

1.  Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.

Authors:  Fangdi Sun; James P Grenert; Lisa Tan; Jessica Van Ziffle; Nancy M Joseph; Claire K Mulvey; Emily Bergsland
Journal:  JCO Precis Oncol       Date:  2022-06

Review 2.  Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches.

Authors:  Carlotta Ceccon; Valentina Angerilli; Cosimo Rasola; Letizia Procaccio; Marianna Sabbadin; Francesca Bergamo; Umberto Malapelle; Sara Lonardi; Matteo Fassan
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 3.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

4.  Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry.

Authors:  Federica Zito Marino; Martina Amato; Andrea Ronchi; Iacopo Panarese; Franca Ferraraccio; Ferdinando De Vita; Giuseppe Tirino; Erika Martinelli; Teresa Troiani; Gaetano Facchini; Felice Pirozzi; Michele Perrotta; Pasquale Incoronato; Raffaele Addeo; Francesco Selvaggi; Francesco Saverio Lucido; Michele Caraglia; Giovanni Savarese; Roberto Sirica; Marika Casillo; Eva Lieto; Annamaria Auricchio; Francesca Cardella; Ludovico Docimo; Gennaro Galizia; Renato Franco
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

5.  Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.

Authors:  Kjersti Elvestad Hestetun; Kristine Aasebø; Nina Benedikte Rosenlund; Yvonne Müller; Olav Dahl; Mette Pernille Myklebust
Journal:  Mod Pathol       Date:  2020-07-31       Impact factor: 7.842

6.  Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome.

Authors:  Wei Chen; Heather Hampel; Rachel Pearlman; Dan Jones; Weiqiang Zhao; Mohammed Alsomali; Deborah Knight; Wendy L Frankel
Journal:  Hum Pathol       Date:  2020-07-08       Impact factor: 3.466

7.  Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.

Authors:  Hyunhee Kim; Ka Young Lim; Jin Woo Park; Jeongwan Kang; Jae Kyung Won; Kwanghoon Lee; Yumi Shim; Chul-Kee Park; Seung-Ki Kim; Seung-Hong Choi; Tae Min Kim; Hongseok Yun; Sung-Hye Park
Journal:  Lab Invest       Date:  2021-11-30       Impact factor: 5.662

8.  Molecular mechanisms and differences in lynch syndrome developing into colorectal cancer and endometrial cancer based on gene expression, methylation, and mutation analysis.

Authors:  Hongfeng Li; Liwei Sun; Yan Zhuang; Caijuan Tian; Fang Yan; Zhenzhen Zhang; Yuanjing Hu; Pengfei Liu
Journal:  Cancer Causes Control       Date:  2022-02-11       Impact factor: 2.506

9.  Modeling the effect of prolonged ethanol exposure on global gene expression and chromatin accessibility in normal 3D colon organoids.

Authors:  Matthew Devall; Lucas T Jennelle; Jennifer Bryant; Stephanie Bien; Ulrike Peters; Steven Powell; Graham Casey
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.